The business model of Check Cap Ltd is focused on developing and commercializing an ingestible capsule system for colorectal cancer screenings. This innovative technology, known as the C-Scan, utilizes ultra-low dose X-ray technology to generate 3D images of the colon. By providing a non-invasive and patient-friendly alternative to traditional colonoscopies, Check Cap aims to increase the accessibility and early detection of colorectal cancer. This approach holds great potential in improving global healthcare outcomes and reducing healthcare costs associated with colorectal cancer screenings. As a leader in medical imaging technology, Check Cap Ltd is committed to driving advancements in the field of gastroenterology and revolutionizing cancer diagnostics.

Check Cap Ltd is primarily active in the healthcare industry, specifically in the field of medical diagnostics.

The main competitors of Check Cap Ltd in the market include companies such as Exact Sciences Corporation, Cerner Corporation, and Medtronic plc.

Check Cap Ltd is a pioneering medical technology company founded in 2004. The company focuses on the development of innovative capsule-based solutions for the medical imaging industry. Check Cap Ltd specializes in developing the C-Scan® system, a patient-friendly device designed to detect colorectal polyps and other gastrointestinal abnormalities. With cutting-edge imaging technology and a commitment to improving patient care, Check Cap Ltd has become a leading player in the medical imaging industry. Known for its dedication to innovation and its focus on improving diagnostic procedures, Check Cap Ltd continues to make significant advancements in the field of gastrointestinal imaging.

Check Cap Ltd has achieved several significant milestones in its journey. Some notable achievements include the successful completion of clinical trials for its C-Scan system, which is a revolutionary ingestible capsule for colorectal cancer screening. The company has also obtained CE Mark approval for the C-Scan system, allowing it to be marketed and sold in Europe. In addition, Check Cap Ltd has entered into partnerships and collaborations with renowned healthcare institutions and industry leaders, further enhancing its position in the market. These milestones highlight Check Cap Ltd's commitment to developing innovative solutions for early detection and prevention of colorectal cancer.

Check Cap Ltd is primarily present in Israel, the United States, and Europe.

Check Cap Ltd is committed to upholding strong values and a clear corporate philosophy. As a company specializing in medical diagnostics, Check Cap prioritizes integrity, innovation, and excellence in its operations. By developing cutting-edge technologies, Check Cap aims to revolutionize the field of screening and early detection of colorectal cancer. The company's core philosophy revolves around patient care, providing non-invasive solutions for effective diagnosis. Check Cap Ltd strives to foster an environment of trust, transparency, and social responsibility, driving its commitment to improving healthcare outcomes and enhancing patients' lives.

6 analysts currently rate the Check Cap stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Check Cap to generate revenue of 76,27 Mio. USD and earnings per share of -2,22 USD.

Check Cap Prezzi Obiettivo Analisti 2026

Converted at the current exchange rate, the Check Cap share trades at 0,92 EUR (1,06 USD).

The Check Cap share (MBAI) is listed on 3 stock exchanges, including: NASDAQ (CHEK), Frankfurt (7CC.F), München (7CC.MU).

Check Cap Ltd is a research-based medical technology company based in Israel. It develops products for the prevention, diagnosis, and monitoring of gastroenterological diseases, with its core product being the C-Scan®. The C-Scan® is a non-invasive, capsule-based technology that allows for the scanning of the entire digestive tract to detect potential tumors or other abnormalities early on. It offers an alternative to traditional colonoscopies and improves diagnostic accuracy. The C-Scan® is easy to use, painless, and requires no prior preparation or cleaning of the colon. Check Cap also conducts clinical studies to develop and test medications for gastroenterological diseases and works on new technologies for better visualization of the digestive tract. Its business model combines research and development, clinical studies, product development, and partnerships with other companies and institutions. With its innovative technology, Check Cap has the potential to change the way gastroenterological diseases are diagnosed, treated, and monitored.

Il attesa fatturato di Check Cap ammonta a 76,27 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.

Il attesa profitto di Check Cap ammonta a -15,60 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.

Il rapporto prezzo/utili (P/E) di Check Cap è attualmente -0,48. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Check Cap.

Il rapporto prezzo/fatturato (P/S) di Check Cap è attualmente 0,10. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Check Cap.

Il Quality Score AlleAktien per Check Cap è 2/10.

L'ISIN di Check Cap è IL0011336851. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.

Il WKN di Check Cap è A14QUF. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.

Il ticker di Check Cap è MBAI. Con questo simbolo di borsa vengono negoziate le azioni Check Cap in borsa.

Check Cap ha pagato dividendi ogni anno negli ultimi 0 anni.

Check Cap è assegnato al settore 'Sanità'.

I dividendi di Check Cap sono distribuiti in USD.